Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: The company said the trial will continue unchanged as per the recommendation of a data monitoring committee. The trial was testing Bristol-Myers’ drugs Opdivo and Yervoy, against Opdivo alone, in patients with advanced melanoma. The combination failed to show a statistically significant benefit in patients whose tumors had 1% or lower levels of the PD-L1 protein being targeted, the company said. The American Cancer Society estimates that about 96,480 melanoma cases will be diagnosed in the United States this year. Bristol-Myers shares were trading at $55.99 before the bell.
[EX A]: Bristol-Myers misses main goal of late-stage skin cancer trial.

[EX Q]: Luke Miels, who joined GSK in September 2017 after a contract dispute with his former employer AstraZeneca, said picking the most promising projects and developing them quickly now takes precedence over spreading the risk of failure. “In the past, 10 programs were chosen, a budget for eight was allocated. Usually what happened was that time was the trade off that was made,” he said in an interview. “Now what we do is we pick five or six programs, and concentrate investment there.”   GSK, like rivals, was in the habit of testing new drugs first on patients who had run out of other treatment options. If successful, it would try patients at an earlier stage of their disease, replacing older, established treatments. In today’s market, where rivals in the United States and China catch up fast if a new class of drug shows promise, GSK has to run costly drug tests on humans in several settings at the same time, even if it means dropping other drug candidates. “Rather than do things sequentially, you do them in parallel, or as close to parallel as possible,” Miels said. GSK, which is battling to return to profit growth, has taken this approach for instance with an experimental drug that for now goes by the code name of GSK’916 against multiple myeloma, a common and incurable type of blood cancer. Likewise, GSK doubled down on its quest to bring a drug known as GSK’165 to market as a rheumatoid arthritis treatment, even after initial results in a mid-stage drug trial did not show a clear enough reading. “This drug has very interesting effects on pain. That could potentially reduce the use of opioids and pain meds,” Miels said. More trials will be run to make the pain argument more clearly, he added. GSK expects a decline of 5%-9% in adjusted earnings per share this year, excluding exchange rate moves, as it suffers from generic competition to its inhalable lung drug Advair and pressure from rival Gilead in HIV treatments. Miels said a tougher stance on drug prices by U.S. lawmakers and medical insurers was one of the reasons for the need for speed in bringing drugs to market - to try to remain ahead of competitors for as long as possible. At the same time, rapid growth in the Chinese market was spurring a more sophisticated healthcare system there, with local biotech groups quick to catch up with Western pioneers in drug development, producing similar drugs for their home market.
[EX A]: GSK pharma head flags need for speed in high-pressure drug market.

[EX Q]: Although the story suggests that the therapy can be expensive, this is not sufficient information on costs. The story does provide quantification of benefits in absolute terms for the 10-week and 4-week psychotherapy groups compared to no treatment. The story does not provide detail on the hypnotherapy studies. The story states that psychotherapies are “without side effects.” While that may reflect the existing data, it would have been preferable for the story to comment on potential side effects or harms without dismissing them. The story provides sufficient details about the design of the recent studies. The story could have provided additional details on the hypnotherapy studies cited. We are told that “just over half” of patients in the hypnotherapy group improved, while no patients in the control groups improved, but we are not given numbers or definition of “improved.” By accurately describing the prevalence of IBS, the story avoids disease mongering. The story quotes multiple sources. The story mentions drug treatment as the alternative. The story could have provided more information on lifestyle changes like diet and exercise. The story clearly states that cognitive behavioral therapy is available, but it is not clear how widely available it is and how difficult it may be to find a practitioner. The story clearly states that psychotherapy has been around for a while, but that it is a new approach for treating IBS. Because the story quotes multiple sources, the reader can assume that the story does not rely on a press release as the sole source of information. Although there was a press release issued from the meeting, the story does not lift text from it and the story also quotes researchers who were not included in the press release.
[EX A]:
The mind as a path to comfort